S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NASDAQ:BCPC - Balchem Stock Price, Forecast & News

$97.14
-0.08 (-0.08 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$96.25
Now: $97.14
$98.57
50-Day Range
$97.14
MA: $107.94
$113.60
52-Week Range
$82.33
Now: $97.14
$113.93
Volume62,193 shs
Average Volume95,745 shs
Market Capitalization$3.13 billion
P/E Ratio39.49
Dividend Yield0.53%
Beta1.07
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Read More…

Industry, Sector and Symbol

Industry Chemicals & allied products
Sub-IndustrySpecialty Chemicals
SectorBasic Materials
Current SymbolNASDAQ:BCPC
CUSIP05766520
CIK9326
Phone845-326-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$643.71 million
Cash Flow$4.51 per share
Book Value$23.06 per share

Profitability

Net Income$79.67 million

Miscellaneous

Employees1,135
Market Cap$3.13 billion
Next Earnings Date5/1/2020 (Estimated)
OptionableOptionable

Receive BCPC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCPC and its competitors with MarketBeat's FREE daily newsletter.


Balchem (NASDAQ:BCPC) Frequently Asked Questions

What is Balchem's stock symbol?

Balchem trades on the NASDAQ under the ticker symbol "BCPC."

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem declared an annual dividend on Wednesday, December 18th. Stockholders of record on Monday, December 30th will be paid a dividend of $0.52 per share on Friday, January 17th. This represents a dividend yield of 0.51%. The ex-dividend date of this dividend is Friday, December 27th. This is a boost from Balchem's previous annual dividend of $0.47. View Balchem's Dividend History.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) issued its earnings results on Friday, February, 21st. The basic materials company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.84 by $0.04. The basic materials company had revenue of $166.50 million for the quarter, compared to analysts' expectations of $165.55 million. Balchem had a return on equity of 14.20% and a net margin of 12.38%. The company's quarterly revenue was up 1.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. View Balchem's Earnings History.

When is Balchem's next earnings date?

Balchem is scheduled to release their next quarterly earnings announcement on Friday, May 1st 2020. View Earnings Estimates for Balchem.

What price target have analysts set for BCPC?

2 analysts have issued 1-year price targets for Balchem's shares. Their forecasts range from $100.00 to $116.00. On average, they anticipate Balchem's share price to reach $108.00 in the next year. This suggests a possible upside of 11.2% from the stock's current price. View Analyst Price Targets for Balchem.

What is the consensus analysts' recommendation for Balchem?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Balchem.

What are Wall Street analysts saying about Balchem stock?

Here are some recent quotes from research analysts about Balchem stock:
  • 1. According to Zacks Investment Research, "Balchem Corporation provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. Balchem Company consists of four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications. " (2/26/2020)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a comparable universe-derived EV-to-EBITDA multiple approach. EV-to-EBITDA multiple to our 2019 diluted EBITDA per share of $3.64, we derive a target of $110 per share. Risks include, but are not limited to: (1) slower-than-anticipated growth in Balchem’s base businesses; (2) a global fracking industry slowdown; (3) inability to launch new nutrition segment products; and (4) failure by Balchem’s partner Curemark to obtain approval for its autism drug candidate." (5/6/2019)

Has Balchem been receiving favorable news coverage?

News headlines about BCPC stock have trended somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Balchem earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave press coverage about the basic materials company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Balchem.

Are investors shorting Balchem?

Balchem saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 556,700 shares, a decrease of 8.8% from the January 30th total of 610,400 shares. Based on an average daily volume of 103,100 shares, the short-interest ratio is currently 5.4 days. Currently, 1.7% of the company's stock are sold short. View Balchem's Current Options Chain.

Who are some of Balchem's key competitors?

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Opko Health (OPK), CVS Health (CVS), Altria Group (MO), Starbucks (SBUX), Walgreens Boots Alliance (WBA), AbbVie (ABBV), AT&T (T), Analog Devices (ADI), Glacier Bancorp (GBCI) and Gilead Sciences (GILD).

Who are Balchem's key executives?

Balchem's management team includes the folowing people:
  • Mr. Theodore L. Harris, Chairman and Chief Exec. Officer (Age 54)
  • Mr. William A. Backus CPA, Chief Accounting Officer (Age 53)
  • Mr. Mark A. Stach, Gen. Counsel & Corp. Sec.
  • Mr. David F. Ludwig, VP & Gen. Mang. of Industrial Products (Age 61)
  • Mr. Carl Martin Bengtsson, Chief Financial Officer

Who are Balchem's major shareholders?

Balchem's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (2.91%), Conestoga Capital Advisors LLC (2.52%), Fred Alger Management LLC (2.06%), Geode Capital Management LLC (1.36%), New York State Common Retirement Fund (1.33%) and Janus Henderson Group PLC (1.26%). Company insiders that own Balchem stock include Daniel E Knutson, David F Ludwig and Scott C Mason. View Institutional Ownership Trends for Balchem.

Which institutional investors are selling Balchem stock?

BCPC stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, PNC Financial Services Group Inc., Bank of New York Mellon Corp, Arizona State Retirement System, Bank of America Corp DE, Royce & Associates LP, GW&K Investment Management LLC and First Trust Advisors LP. View Insider Buying and Selling for Balchem.

Which institutional investors are buying Balchem stock?

BCPC stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Great West Life Assurance Co. Can, Goldman Sachs Group Inc., Sei Investments Co., Geode Capital Management LLC, Aviva PLC, Barclays PLC and Charles Schwab Investment Management Inc.. Company insiders that have bought Balchem stock in the last two years include Daniel E Knutson and Scott C Mason. View Insider Buying and Selling for Balchem.

How do I buy shares of Balchem?

Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Balchem's stock price today?

One share of BCPC stock can currently be purchased for approximately $97.14.

How big of a company is Balchem?

Balchem has a market capitalization of $3.13 billion and generates $643.71 million in revenue each year. The basic materials company earns $79.67 million in net income (profit) each year or $3.19 on an earnings per share basis. Balchem employs 1,135 workers across the globe.View Additional Information About Balchem.

What is Balchem's official website?

The official website for Balchem is http://www.balchem.com/.

How can I contact Balchem?

Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at 845-326-5600 or via email at [email protected]


MarketBeat Community Rating for Balchem (NASDAQ BCPC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  293 (Vote Underperform)
Total Votes:  626
MarketBeat's community ratings are surveys of what our community members think about Balchem and other stocks. Vote "Outperform" if you believe BCPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel